Home

RANDY H THURMAN

CIK 1204059 · Executive Chairman · last filed 2026-05-27

RANDY H THURMAN is an Executive Chairman who has filed 56 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider bought $2.1K of OTLK on May 27, 2026. Across all open-market trades the lifetime net is −$393.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions. 9 SEC filings were submitted jointly with ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.37M

Companies

10

Total Filings

56

Lifetime Open-Market Net

-$393.9K

Filer Profile

Reported Address
222 MERCHANDISE MART PLAZA
SUITE 2024
CHICAGO, IL 60654
Related Filers
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. — 9 joint filings, latest 2017-05-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK Director 5,593 $0.67 $3.7K $2.1K 6 2026-05-27
TFF Pharmaceuticals, Inc. (TFFP) Delisted Director 0 $0.07 $0 -$772.6K 6 2022-09-30
Outlook Therapeutics, Inc. (OTLKW) Delisted Director 11,875 $0.03 $356 $16.5K 8 2021-03-26
Outlook Therapeutics, Inc. (ONSIW) Delisted Director — — — $0 3 2018-11-13
Outlook Therapeutics, Inc. (ONSIZ) Delisted Director — — — $0 1 2018-04-17
Veradigm Inc. (MDRX) Delisted Director 105,014 $6.81 $715.1K $150.8K 7 2017-05-24
LENS Executive Chairman 47,757 $47.11 $2.25M $109.5K 6 2017-03-22
OFIX Director — $9.29 — $0 1 2013-11-21
BEAT Chairman, President & CEO 264,766 $0.43 $113.0K $99.8K 10 2011-05-03
VIASYS HEALTHCARE INC (VAS) Delisted Chairman, President & CEO 51,334 — — $0 3 2007-06-25

Recent Filings

56 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-27 OTLK Buy (P) +5,000 $2.1K EDGAR
2025-10-03 OTLK Grant (A) — $0 EDGAR
2024-10-03 OTLK Grant (A) — $0 EDGAR
2024-03-08 OTLK Grant (A) — $0 EDGAR
2023-03-31 OTLK Grant (A) — $0 EDGAR
2022-09-30 TFF Pharmaceuticals, Inc. (TFFP) Delisted Mixed — -$72.1K EDGAR
2022-03-24 OTLK Grant (A) — $0 EDGAR
2021-05-19 TFF Pharmaceuticals, Inc. (TFFP) Delisted Buy (P) +1,050 $9.9K EDGAR
2021-03-26 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) — $0 EDGAR
2020-11-13 TFF Pharmaceuticals, Inc. (TFFP) Delisted Mixed −5,000 -$548.5K EDGAR
Showing 1–10 of 56
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.